# A Study of HS-20124 in Patients with Advanced Solid Tumors

> **NCT06763159** · PHASE1 · RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 450 (estimated)

## Conditions studied

- Solid Cancer

## Interventions

- **DRUG:** HS-20124 (Phase Ia：Dose escalation )
- **DRUG:** HS-20124 (Phase Ib: Dose expansion)

## Key facts

- **NCT ID:** NCT06763159
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-30
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2025-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06763159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06763159, "A Study of HS-20124 in Patients with Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06763159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*